Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review

World Journal of Biological Psychiatry

Volumn 14, Issue 6, 2013, Pages 412-431

  Pompili, Maurizio ^a   Serafini, Gianluca ^a   Innamorati, Marco ^a   Venturini, Paola ^a   Fusar Poli, Paolo ^b   Sher, Leo ^c   Amore, Mario ^d   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Agomelatine; Antidepressant drugs; Efficacy; Neuroplasticity; Tolerability

Indexed keywords

AGOMELATINE; AMINOTRANSFERASE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LITHIUM; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MONOAMINE; PAROXETINE; SEROTONIN 2C RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROMIDE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; CIRCADIAN RHYTHM; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON ANXIETY SCALE; HIPPOCAMPUS; HUMAN; LEEDS SLEEP EVALUATION QUESTIONNAIRE; MAJOR AFFECTIVE DISORDER; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEUROGENESIS; NEURONAL PLASTICITY; RECEPTORS, MELATONIN; TREATMENT OUTCOME;

EID: 84882757504     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2013.765593     Document Type: Review

References (102)

1. AlAhmed S, Herbert J. 2010. Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropharmacology 59: 375-379
2. Alarma-Estrany P, Pintor J. 2007. Melatonin receptors in the eye: Location, second messengers and role in ocular physiology. Pharmacol Ther 113: 507-522
3. Anderson IM. 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of effi cacy and tolerability . J Affect Disord 58(1): 19-36
4. Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I. 2008. Chronic antidepressant treatments increase basic fi broblast growth factor and fi broblast growth factor-binding protein in neurons. Neuropharmacology 55: 1114-1120
5. Balu DT, Lucki I. 2009. Adult hippocampal neurogenesis: Regulation, functional implications, and contribution to disease pathology. Neurosci Biobehav Rev 33: 232-252
6. Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. 2006. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 59: 1087-1096
7. Barbiero VS, Giambelli R, Musazzi L, Tiraboschi E, Tardito D, Perez J, et al. 2007. Chronic antidepressants induce redistribution and differential activation of aCaM kinase II between presynaptic compartments. Neuropsychopharmacology 32: 2511-2519
8. Barden N, Shink E, Labbé M, Vacher R, Rochford J, Mocaër E. 2005. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 29: 908-916
9. Belmaker RH. 2008. The future of depression psychopharmacology. CNS Spectr 13(8): 682-687
10. Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaër E. 2006. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17: 703-713
11. Berton O, Nestler EJ. 2006. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 7: 137-151
12. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, et al. 2009. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 14(8): 764-773
13. Bourin M, Mocaër E, Porsolt R. 2004. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: Involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 29: 126-133
14. Cajochen C, Kräuchi K, Möri D, Graw P, Wirz-Justice A. 1997. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol 272(4 Pt 2): R1189-1196
15. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. 2007. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord 9(6): 628-635
16. Calabrese F, Molteni R, Racagni G, Riva MA. 2009. Neuronal plasticity: A link between stress and mood disorders. Psychoneuroendocrinology 34(Suppl 1): S208-216
17. Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, et al. 2010. Long-term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specifi c neurotrophin isoforms. Mol Pharmacol 77(5): 846-853
18. Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA. 2011. Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology 215(2): 267-275
19. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, et al. 2004. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36: 827-835
20. Castren E. 2005. Is mood chemistry? Nat Rev Neurosci 6: 241-246
21. Castren E, Voikar V, Rantamaki T. 2007. Role of neurotrophic factors in depression. Curr Opin Pharmacol 7: 18-21
22. Conboy L, Tanrikut C, Zoladz PR, Campbell AM, Park CR, Gabriel C, et al. 2009. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 12: 329-341
23. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy Julie A. 2002. cAMP Response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22(8): 3262-3268
24. Dagyte G, Trentani A, Postema F, Luiten PG, Den Boer JA, Gabriel C, et al. 2010. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther 16(4): 195-207
25. Dagyte G, Luiten PG, De Jager T, Gabriel C, Mocaër E, Den Boer JA, et al. 2011. Chronic stress and antidepressant agomelatine induce region-specifi c changes in synapsin I expression in the rat brain. J Neurosci Res 89(10): 1646-1657
26. Daszuta A, Ban M Sr, Soumier A, Hery M, Mocaer E. 2005. [Depression and neuroplasticity: Implication of serotoninergic systems]. Therapie 60(5): 461-468
27. Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, et al. 2011. Major depressive disorder, anhedonia and agomelatine: An open-label study. J Biol Regul Homeost Agents 25(1): 109-114
28. Dubocovich ML, Riviera-Bermudez MA, Gerdin MJ, Masana MI. 2003. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8: D1093-1098
29. Duman RS. 2004. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 5: 11-25
30. Duman RS, Malberg J, Thome J. 1999. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46(9): 1181-1191
31. Eriksson PS, Perfi lieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. 1998. Neurogenesis in the adult human hippocampus. Nat Med 4(11): 1313-1317
32. European Medicines Agency. 2008. CMHP assessment report for valdoxan. 20 November 2008 [online]. Available from URL: Http://www.ema.europa.eu/docs/en-GB/ document- library/ EPAR--Public-assessment-report/human/000915/ WC500046226.pdf [accessed 1 November 2012].
33. Fornaro M, Prestia D, Colicchio S, Perugi G. 2010. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 8(3): 287-304
34. Fuchs E. 2009. Neuroplasticity: A new approach to the pathophysiology of depression. In: Costa e Silva JA, Macher JP, Olié JP, editors. Neuroplasticity: New biochemical mechanisms. UK: Current Medicine Group. p 1-12
35. Goodwin GM, Emsley R, Rembry S, Rouillon F ; Agomelatine Study Group. 2009. Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70(8): 1128-1137
36. Grassi-Zucconi G, Semprevivo M, Mocaer E, Kristensson K, Bentivoglio M. 1996. Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat. Brain Res Bull 39(2): 63-68
37. Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12(12): 1079-1088
38. Hagg T. 2005. Molecular regulation of adult CNS neurogenesis: An integrated view. Trends Neurosci 28(11): 589-595
39. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. 2010. Superior antidepressant effi cacy results of agomelatine versus fl uoxetine in severe MDD patients: A randomized, double-blind study. Int Clin Psychopharmacol 25(6): 305-314
40. Hanoun N, Mocaër E, Boyer PA, Hamon M, Lanfumey L. 2004. Differential effects of the novel antidepressant agomelatine (S 20098) versus fl uoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 47(4): 515-526
41. Kasper S, Hamon M. 2009. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 10(2): 117-126
42. Kasper S, McEwen BS. 2008. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 22(1): 15-26
43. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. 2010. Effi cacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71: 109-120
44. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Salva MA. 2013. Antidepressant effi cacy of agomelatine versus SSRI/SNRI: Results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 28(1): 12-19
45. Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16(2): 93-100
46. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. 2008. A doubleblind comparison of sexual functioning, antidepressant effi cacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28(3): 329-333
47. Kim MJ, Kim HK, Kim BS, Yim SV. 2004. Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats. J Pineal Res 37(3): 193-197
48. Kozisek ME, Middlemas D, Bylund DB. 2008. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 117(1): 30-51
49. Kräuchi K, Cajochen C, Möri D, Graw P, Wirz-Justice A. 1997. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 272 (4 Pt 2): R1178-1188
50. Larsen MH, Hay-Schmidt A, Rønn LCB, Mikkelsen JD. 2008. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur J Pharmacol 578: 114-122
51. Lemoine P, Guilleminault C, Alvarez E. 2007. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68(11): 1723-1732
52. Lôo H, Hale A, D'Haenen H. 2002a. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychopharmacol 17(5): 239-247
53. Lôo H, Dalé ry J, Macher JP, Payen A. 2002b. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]. Encephale 28(4): 356-362
54. Lôo H, Dalery J, Macher A, Payen JP. 2003. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninagonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]. Encephale 29(2): 165-171
55. Lopes MC, Quera-Salva MA, Guilleminault C. 2007. Non-REM sleep instability in patients with major depressive disorder: Subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 9(1): 33-41
56. Manji HK, Duman RS. 2001. Impairments of neuroplasticity and cellular resilience in severe mood disorders: Implications for the development of novel therapeutics. Psychopharmacol Bull 35(2): 5-49
57. Manji HK, Moore GJ, Rajkowska G, Chen G. 2000. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5(6): 578-593
58. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, et al. 2003. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for diffi cult to treat depression. Biol Psychiatry 53(8): 707-742
59. Masana MI, Doolen S, Ersahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, Krause DN. 2002. MT2 melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther 302(3): 1295-1302
60. Mathers CD, Vos ET, Stevenson CE, Begg SJ. 2000. The Australian Burden of Disease Study: Measuring the loss of health from diseases, injuries and risk factors. Med J Aust 172(12): 592-596
61. Mattson MP, Maudsley S, Martin B. 2004. BDNF and 5-HT: A dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27(10): 589-594
62. McEwen BS, Chattarji S. 2004. Molecular mechanisms of neuroplasticity and pharmacological implications: The example of tianeptine. Eur Neuropsychopharmacol 14(Suppl 5): S497-502
63. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Br Med J 339: B2535
64. Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, et al. 2010. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 11(2): 148-153
65. Montgomery S, Kasper AS. 2007. Severe depression and antidepressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22(5): 283-291
66. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. 2004. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19(5): 271-280
67. Morley-Fletcher S, Mairesse J, Soumier A, Banasr M, Fagioli F, Gabriel C, et al. 2011. Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 217(3): 301-313
68. Naji L, Carrillo-Vico A, Guerrero JM, Calvo Jr. 2004. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 74(18): 2227-2236
69. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. 2002. Neurobiology of depression. Neuron 34(1): 13-25
70. Novartis. Clinical trial results database [online]. Available from URL: Http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ public.jsp?divisionId - 2 & diseaseAreaID - 3 [accessed 1 November 2012].
71. Olié JP, Kasper S. 2007. Effi cacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10(5): 661-673
72. Païzanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C, et al. 2010. Behavioural and neuroplastic effects of the newgeneration antidepressant. Int J Neuropsychopharmacol 13(6): 759-774
73. Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ. 2006 Could agomelative be the ideal antidepressant? Exp Rev Neurother6(11): 1595-1608
74. Papakostas GI, Fava M. 2008. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialog Clin Neurosci 10(4): 439-451
75. Papp M, Gruca P, Boyer PA, Mocaër E. 2003 Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28(4): 694-703
76. Perez-Cruz C, Müller-Keuker JI, Heilbronner U, Fuchs E, Flügge G. 2007. Morphology of pyramidal neurons in the rat prefrontal cortex: Lateralized dendritic remodeling by chronic stress. Neural Plast 2007: 46276
77. Perez-Cruz C, Simon M, Czé h B, Flügge G, Fuchs E. 2009. Hemispheric differences in basilar dendrites and spines of pyramidal neurons in the rat prelimbic cortex: Activity-and stress-induced changes. Eur J Neurosci 29(4): 738-747
78. Pittenger C, Duman RS. 2008. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 33(1): 88-109
79. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. 2007. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berlin) 190(4): 575-579
80. Pompili M, Serafi ni G, Del Casale A, Rigucci S, Innamorati M, Girardi P, et al. 2009a. Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 9(7): 985-1004
81. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. 2009b. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother 9(1): 109-136
82. Pozo D, Delgado M, Fernandez-Santos JM, Calvo JR, Gomariz RP, Martin-Lacave I, et al. 1997. Expression of the Mel1amelatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 11(6): 466-473
83. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. 2007. Major depressive disorder, sleep EEG and agomelatine: An open-label study. Int J Neuropsychopharmacol 10(5): 691-696
84. Racagni G, Popoli M. 2008. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialog Clin Neurosci 10(4): 385-400
85. Reagan LP, Rosell DR, Wood GE, Spedding M, Mu ñ oz C, Rothstein J, et al. 2004. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine. Proc Natl Acad Sci USA 101: 2179-2184
86. Reznikov LR, Fadel JR, Reagan LP. 2009. Glutamate-mediated neuroplasticity defi cits in mood disorders. In: Costa e Silva JA, Macher JP, Olié JP, editors. Neuroplasticity: New biochemical mechanisms. UK: Current Medicine Group. p 13-26
87. Richter HG, Torres-Farfan C, Garcia-Sesnich J, Abarzua-Catalan L, Henriquez MG, Alvarez-Felmer M, et al. 2008. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. Endocrinology 149(3): 995-1003
88. Rush AJ. 2007. STAR * D. what have we learned? Am J Psychiatry 164(2): 201-204
89. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, et al. 2006. Report by the ACNP task force on response and remission in major depression. Neuropsychopharmacol 31: 1841-1853
90. Sairanen M, O'Leary OF, Knuuttila JE, Castré n E. 2007. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 144(1): 368-374
91. Sallinen P, Saarela S, Ilves M, Vakkuri O, Leppäluoto J. 2005. The expression of MT1 and MT2 melatonin receptor mRNAin several rat tissues. Life Sci 76(10): 1123-1134
92. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. 2008. Melatonin in the skin: Synthesis, metabolism and functions Trends Endocrinol Metab 19(1): 17-24
93. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, et al. 2009. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34(11): 2390-2403
94. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. 2010. Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 71(5): 616-626
95. Tardito D, Milanese M, Bonifacino T, Musazzi L, Grilli M, Mallei A, et al. 2010. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptordependent pathways. BMC Neurosci 11: 68
96. Trivedi MH, Daly EJ. 2008. Treatment strategies to improve and sustain remission in major depressive disorder. Dialog Clin Neurosci 10(4): 377-384
97. Van Reeth O, Olivares E, Zhang Y, Zee PC, Mocaer E, Defrance R, et al. 1997. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 762(1-2): 185-194
98. Van Reeth O, Olivares E, Turek FW, Granjon L, Mocaer E. 1998. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 9(8): 1901-1905
99. Weibel L, Turek FW, Mocaer E, Van Reeth O. 2000. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 880(1-2): 207-211
100. Wu YH, Zhou JN, Balesar R, Unmehopa U, Bao A, Jockers R, Van Heerikhuize J, Swaab DF. 2006. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol 499(6): 897-910
101. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. 2010. Effi cacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30(2): 135-144
102. Zawilska JB, Skene DJ, Arendt JJ. 2009. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 61(3): 383-410